Approved as VYLEESI (bremelanotide) for hypoactive sexual desire disorder (HSDD) in premenopausal women, FDA approval 2019.
Bremelanotide is a synthetic cyclic heptapeptide analogue of alpha-MSH that acts as a nonselective melanocortin receptor agonist, with activity at both MC4R and MC3R. Central MC4R activation is unders...
Bremelanotide is a synthetic cyclic heptapeptide analogue of alpha-MSH that acts as a nonselective melanocortin receptor agonist, with activity at both MC4R and MC3R. Central MC4R activation is understood to modulate hypothalamic circuits implicated in sexual arousal and desire, distinguishing its mechanism from peripheral vascular-acting agents. It has an unusually deep human clinical trial record among research peptides, including a 52-week long-term safety extension.
Drugs · 2019
Documents bremelanotide's 2019 FDA approval as the first melanocortin receptor agonist for HSDD in premenopausal women.
View Source →Obstetrics & Gynecology · 2019
52-week open-label extension of the pivotal trials found no new safety signals, with sustained desire improvements; nausea, flushing, and headache were the most common adverse effects.
View Source →Journal of Sexual Medicine · 2006
Crossover study found more women reported moderate-to-high desire after intranasal bremelanotide versus placebo during erotic video exposure, though vaginal vasocongestion was not significantly changed.
View Source →